[Effects of ulinastatin on PMNL and vascular endothelial injury in patients undergoing open heart surgery with CPB].
Activated leukocytes are thought to contribute to respiratory dysfunction, alterations in microvascular permeability, disseminated intravascular coagulation, and thrombosis, all of which can complicate cardiopulmonary bypass (CPB). We have measured the levels of circulating proinflammatory cytokines (IL-6, 8), polymorphonuclear leukocytes elastase (PMNL-E), and vascular endthelial factors (ET-1, TM, sICAM-1) in patients undergoing open heart surgery with CPB. Patients were divided into a control group and a ulinastatin group. We have examined the effects of ulinastatin on these humoral mediators and postoperative pulmonary function. Every factor except IL-8 increased after CBP in control group. IL-6 and PMNL-E declined sharply to normal level in a few hours, but it took several days after surgery for ET-1, TM, and sICAM-1 to return to preoperative levels. Ulinastatin significantly suppressed the elevation of PMNL-E after CPB, indirectly suppressing the increase of other factors. There was no significant relationship between levels of humoral mediators and postoperative pulmonary function between the two groups. Our results suggest that ulinastatin alleviates the damage of vascular endothelium due to CPB (first attack), and this may be beneficial to reduce excessive inflammatory reaction against secondary insults.
Miura
M
M
Department of Anesthesia, Gifu Prefectural Tajimi Hospital.
Sugiura
T
T
Aimi
Y
Y
Yasuda
K
K
Ito
S
S
Baba
E
E
Katsuya
H
H
D000368:Aged; D002199:Capillary Permeability; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D019332:Endothelin-1 / Q000097:blood; D004730:Endothelium, Vascular / Q000473:pathology*; D006023:Glycoproteins / Q000008:administration & dosage*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D019272:Leukocyte Elastase / Q000097:blood; D008168:Lung / Q000503:physiopathology*; D008875:Middle Aged; D018375:Neutrophil Activation / Q000502:physiology*; D012120:Respiration Disorders / Q000503:physiopathology / Q000517:prevention & control; D014361:Trypsin Inhibitors / Q000008:administration & dosage*
D019332:Endothelin-1; D006023:Glycoproteins; D014361:Trypsin Inhibitors; D018799:Intercellular Adhesion Molecule-1; D019272:Leukocyte Elastase; C028665:urinastatin